1 completed, 1 not yet recruiting, 1 withdrawn. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 1, Not yet recruiting 1, Withdrawn 1 |
Follow pomalidomide: new trials by email Literature Review of pomalidomide trials Research Report on pomalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response Pomalidomide, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 4 | Not yet recruiting | The First Hospital of Jilin University | 27 | 2026-09-01 | 2026-08-12 |
| Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study Pomalidomide 4 mg every day in cycle 1, Pomalidomide 4 mg every other day in cycle 2, Pomalidomide 2 mg every day in cycle 2 - Multiple Myeloma in Relapse, Multiple Myeloma | Phase 4 | Completed | Amsterdam UMC, location VUmc | 12 | 2022-12-01 | 2025-04-22 |
| A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma Ixazomib, Pomalidomide, Lenalidomide - Multiple Myeloma | Phase 4 | Withdrawn | Takeda | 2022-06-30 | 2022-05-03 |
Multiple Myeloma (2) · Lymphoma, Large B-Cell, Diffuse (1)
Amsterdam UMC, location VUmc (1) · Takeda (1) · The First Hospital of Jilin University (1)
Netherlands (1)